New pharma genotoxic impurity application note on TSQ Quantis™ LC-MS/MS
• A single method capable of detecting an azido impurity (AZBT) in six different
Sartan products—Candesartan, Irbesartan, Losartan, Olmesartan, Telmisartan, and Valsartan—saves time by testing multiple products in one sequence without separate
• A robust method for quantification of AZBT was achieved by using a divert valve to
prevent the mass spectrometer from the build-up of high concentrations of drug
product samples. This helped maintain good sensitivity and reproducibility.
• This study is in line with regulatory information and requirements mentioned in
EDQM1, USFDA (Q2B)2, EMEA3, and ICH M74 guidelines.
an-000748-pb-lc-ms-vanquish-tsq-drug-products-an000748-na-en.pdf (929.1 KB)